Stroke: Competitive Treatments and Market Entry Considerations, 2010

Questions: Discounts, Updates etc.

Pages: 140

Price (Single): £5900

Price (Departmental): £8850

Price (Company): £11800

Publication Date: 2010-06-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In 2008, the World Stroke Congress reported that 20 million Stroke events occur globally each year and account for 5.7 million deaths. Stroke is now the second most common cause of death worldwide and a major cause of disability. The incidence of Stroke is expected to increase by 30% over the next decade (6th World Stroke Congress, Vienna, Austria, 24th-27th September 2008).

In a field where therapies are often unsatisfactory, physicians seek to extend their understanding and use of available treatments to improve patient outcomes. Knowledge in these areas is also important to drug developers, who seek a better understanding of prescribing practices and treatment needs and limitations from the clinician’s perspective, as part of their own efforts to develop more effective therapies. To meet interest in these areas, Biopharm Reports has conducted a global survey on current treatments and drug prescribing practices for Stroke. This survey involved the participation of more than 230 clinical centres in 41 countries.

Overview:

Table of Contents

Report Contents

1. Introduction
2. Stroke therapy survey
3. Survey participants
4. Stroke diagnosis
5. Limitations of stroke diagnostics
6. Drug Classes used to treat transient Ischaemic attack (TIA)
7. Drug classes used to treat Ischaemic Stroke
8. Antiplatelet drugs used to treat Ischaemic Stroke
9. Anticoagulant drugs used to treat Ischaemic Stroke
10. Thrombolytic drugs used to treat Ischaemic Stroke
11. Combined drugs used to treat Ischaemic Stroke
12. The use of drug therapy and/or surgery to treat Haemorrhagic Stroke
13. Drugs used to treat Haemorrhagic Stroke
14. The use of combined drugs to treat Haemorrhagic Stroke
15. Surgical methods to treat Haemorrhagic Stroke
16. Study participants
Appendix 1

Figures


Tables


Appendix

Appendix 1. Responses given by study participants to the question: What are the major issues and challenges associated with the treatment of Stroke? These responses (which in some cases may be brief, informal or abbreviated) are presented verbatim, except in those cases where minor grammatical or typographical corrections have been made for reasons of clarity.

Download Table of Contents as a PDF

Other users found this report page using the following search terms: Ischaemic Stroke Haemorrhagic Stroke stroke Transient Ischaemic Attack TIA stroke prescribing treatment market belgiumhospitalspecialistinstroke occur world 20 asasantin each

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.